Company Description

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Citius Oncology, Inc.

Country	United States
Founded	2021
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Leonard Mazur

Contact Details

Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States
Phone	(908) 967-6677

Stock Details

Ticker Symbol	CTOR
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	October - September
Reporting Currency	USD
CIK Code	0001851484
ISIN Number	US17331Y1091
SIC Code	2834

Key Executives

Name	Position
Leonard L. Mazur	Chief Executive Officer, President and Executive Chairman
Myron Z. Holubiak	Secretary and Executive Vice Chairman
Dr. Myron S. Czuczman M.D.	Chief Medical Officer
Jaime Bartushak	Chief Financial Officer and Treasurer

Latest SEC Filings

Date	Type	Title
Aug 12, 2025	8-K	Current Report
Aug 12, 2025	10-Q	Quarterly Report
Jul 25, 2025	SCHEDULE 13D/A	Filing
Jul 18, 2025	8-K	Current Report
Jul 17, 2025	424B4	Prospectus
Jul 16, 2025	EFFECT	Notice of Effectiveness
Jul 14, 2025	S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
Jul 14, 2025	S-1	General form for registration of securities under the Securities Act of 1933
Jun 27, 2025	8-K	Current Report
Jun 17, 2025	8-K	Current Report

View All SEC Filings